Polymorphism of the ADRB2 gene as a factor of hereditary susceptibility to the development of asthma and response to salbutamol therapy

Livshits, L. A.; Tatarsky, P.F.; Gorodna, Olexandra; Mayakovskaya, A.V.; Volynets, G.P.; Chumachenko, N. G.; Уманец, Т.Р.; Lapshin, V. F.; Antipkin, Yu.G.

doi:10.15574/pp.2019.78.38

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, timely clinical and genetic diagnosis and prognosis of asthma in children with recurrent bronchial obstruction (RBO) makes it possible to avoid burdensome, unnecessary diagnostic and expensive therapeutic measures and to interest parents in the recovery process [12][13][14]. Undertreatment, the presence of an incomplete rehabilitation stage in the process of remission of the disease is one of the reasons for the transformation of acute forms of bronchitis into a recurrent course and chronic pathology.…”

Section: Introductionmentioning

confidence: 99%

Variability of the pharmacological response in children with different ADRB2 gene polymorphisms in recurrent bronchial obstruction and bronchial asthma

Zakirova,

Israilova,

Karimova

et al. 2023

BIO Web Conf.

View full text Add to dashboard Cite

To date, methods of studying the effects of drugs at the molecular-genetic level are widely used in pediatric practice. The aim of our work was to evaluate the effectiveness of the effect of β2-agonists on the clinical course of recurrent bronchial obstruction (RBO) in children, depending on the variants of polymorphism of the ADRB2 gene. The effectiveness of salbutamol in children with RBO and bronchial asthma(BA) was evaluated depending on the distribution of alleles and genotypes of the ADRB2 Argl6Gly and Gln27Glu genes according to the degree of reversibility of bronchial obstruction. In the group of children with RBO carriers of the heterozygous A/G genotype of the Arg16Gly locus and the Gln27Glu locus of the ADRB2 gene, high efficacy of salbutamol therapy as a bronchodilator was noted. At the same time, in children with RBO representatives of the G/G genotype, the effectiveness of using the drug is low. In children with BA, the change in functional activity is associated with the polymorphism of the Gln27Glu gene locus and is associated with a low therapeutic response to β2–agonists in children with the G\G mutational genotype and a good effect in carriers of the homozygous variant with the A/A genotype. Knowledge of the genotype of polymorphic variants of the ADRB2 gene will make it possible to evaluate one of the factors of predisposition and effectiveness of therapy in the recurrent course of bronchial obstruction syndrome and bronchial asthma.

show abstract

Section: Introductionmentioning

confidence: 99%

Variability of the pharmacological response in children with different ADRB2 gene polymorphisms in recurrent bronchial obstruction and bronchial asthma

Zakirova,

Israilova,

Karimova

et al. 2023

BIO Web Conf.

View full text Add to dashboard Cite

show abstract

The role of association of ADRB2 gene polymorphism with therapeutic response to β2-agonists in children with recurrent bronchial obstruction

Каримджанов¹,

Zakirova

Yusupova

et al. 2022

View full text Add to dashboard Cite

Background. The study of the effect of drugs at the molecular genetic level in the recurrent course of bronchial obstruction (RBО) in children improved the understanding of the pathogenesis of the disease and made it possible to better characterize the reliability of use in therapy. The aim of the study was to assess the clinical significance of the polymorphism of the Arg16Gly loci of the ADRB2 gene with a therapeutic response to β2-agonists in children with RBО of Uzbek ethnicity. Materials and methods. Tested 88 patients aged 6 to 15 years with recurrent bronchial obstruction and bronchial asthma with the polymorphism of the ADRB2 gene loci and determined the effectiveness of salbutamol in these groups of patients. Results. Results of the study of the significance of the polymorphism of the Arg16Gly locus of the ADRB2 gene with a therapeutic response to β2-agonists in children with RBO showed high efficacy of salbutamol in 72.9 % of children, among whom representatives of the A/G and A/A genotypes were found in the largest number. At the same time, the low efficacy of salbutamol was found in the greatest amount in carriers of the mutational genotype G/G of the Arg16Gly locus of the ADRB2 gene. Conclusions. The predictor role of the polymorphic locus rs1042713 (Arg16Gly) was determined in carriers of the unfavorable 46G allele of the G/G genotype of the ADRB2 gene, which was a genetic marker of children’s predisposition to RBO and BA in children. Children with the G/G genotype of the Arg16Gly locus of the ADRB2 gene are at risk for severe RBO and BA in children. Children with RBO carriers (Arg16Gly) of the homozygous G/G genotype have a high incidence of RBO recurrence against the background of ARVI and are at risk of developing BA.

show abstract

Polymorphism of the ADRB2 gene as a factor of hereditary susceptibility to the development of asthma and response to salbutamol therapy

Cited by 2 publications

References 32 publications

Variability of the pharmacological response in children with different ADRB2 gene polymorphisms in recurrent bronchial obstruction and bronchial asthma

Variability of the pharmacological response in children with different ADRB2 gene polymorphisms in recurrent bronchial obstruction and bronchial asthma

The role of association of ADRB2 gene polymorphism with therapeutic response to β2-agonists in children with recurrent bronchial obstruction

Contact Info

Product

Resources

About